Contact information
Research groups
Ricardo A. Fernandes
COI Group Leader
The main objective of our research group is to identify key functional aspects affecting anti-tumor responses by T cells. To do this, we use protein engineering, guided by structural and signaling information, to generate novel molecules that allow us to explore and interrogate key aspects of receptor signaling and T cell function. We are currently focusing our efforts in developing molecules to overcome “inhibitory” signaling by immune checkpoint receptors and to enhance signaling by the T-cell receptor.
Ricardo Fernandes recently joined CAMS Oxford Institute coming from Stanford where he developed novel molecules to effectively shut down signaling by immune receptors such as PD-1.
Recent publications
-
Proximity proteomics reveals UCH-L1 as an essential regulator of NLRP3-mediated IL-1β production in human macrophages and microglia
Journal article
Liang Z. et al, (2024), Cell Reports, 43, 114152 - 114152
-
Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis
Journal article
Gupta T. et al, (2024), Cancer Cell, 42, 797 - 814.e15
-
Unconventional human CD61 pairing with CD103 promotes TCR signaling and antigen-specific T cell cytotoxicity
Journal article
Hamid MHBA. et al, (2024), Nature Immunology, 25, 834 - 846
-
TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways
Journal article
Chan W. et al, (2023), Journal of Experimental Medicine, 220
-
Proximity proteomics reveals UCH-L1 as an NLRP3 interactor that modulates IL-1β production in human macrophages and microglia
Preprint
Liang Z. et al, (2023)